Strong growth masks profit decline; strategy credible, execution uncertain
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered 18.8% revenue growth vs stated 15% aspirational (beat), but profit fell sharply vs prior-year baseline. EBITDA margin 18.2% met guidance (18–20%), but PAT conversion weakened. Management refusal to guide quarterly metrics obscures near-term traction.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Management credibly articulates a 5-year engineering/EV/aerospace pivot, with capex and JV mechanisms in place. However, the delivered quarter reveals margin compression: revenue grew 18.8% but PAT fell 12.5%, and OPM declined QoQ despite 4.6% sequential revenue gain. The core risk is whether organic profit growth can materialize while funding JVs and product development.
₹386.4 Cr
Revenue · +18.8% YoY₹36.2 Cr
Reported PAT · −12.5% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue ₹386 Cr, 18.8% YoY growth
Delivered ₹386.4 Cr at 18.8% YoY — exact match
MET
EBITDA ₹71 Cr at 18.2% margin
71/386.4 = 18.4%, within guided 18–20% range
MET
Broad-based growth; CV segment up 47%, Industrial up 48%
Segment growth stated but not audited; overall 18.8% YoY consistent with mix
MET
Quality of growth improved; deeper customer engagement, high-value product mix
PAT fell 12.5% YoY, NPM compressed from ~10.6% YoY to 9.3%, QoQ PAT -4% despite 4.6% revenue growth
MISS
COGS control: costs rose only ~1% despite organic growth
OPM 17.3% delivered; peer COGS typically rise with mix/scale. Unverified but plausible given cost discipline narrative
Partially Supported
Earnings quality
What changed since the last call
Growth trajectory implied raised to 20%
UpgradeManagement said 'moving into growth trajectory towards 20%' (vs prior 14.38% CAGR extrapolation). Informal; no new quantified FY27/28 target given. Prior ₹2,730 Cr FY31 maintained.
Margin expansion timing pushed out
NeutralReaffirmed 18–20% EBITDA goal, but Q2 at lower end (18.2%); management said 'once we reach new threshold' implying scale-dependent. No cut, but cautiousness vs. prior optimism.
Capex phased across ₹270 Cr total unchanged
NeutralUnitec JV (₹110 Cr) on track April 2027. No new capex commitments; investment thesis unchanged.
The Q&A
Analysts pressed hard on quarterly guidance gap (15% prior aspiration vs 19% delivered), segment specificity (non-auto definition), and profit decline. Management deflected with 'conservative' messaging and 'long-term' framing, refusing near-term numeric commitments. Tone was assertive on moat (aerospace, EV readiness) but evasive on cost/mix sensitivity. Management held ground, didn't concede misses.
Growth guidance delta — Siddhart Mantri, InvestQ
DodgedNo, we are a conservative company; we like to over-perform. We are now moving to a 20% growth trajectory. For H2, we will sustain this if capacity and new customer wins materialize.
EBITDA leverage — Siddhart Mantri, InvestQ
PartialWe maintain 17–18% EBITDA ratio. Once we reach a new threshold of growth, we intend to sustain and surpass it. We are not quarterly-driven; annual view.
Unitec JV ramp — Varun Jain, Dolat Capital
AnsweredOn track for April 2027. ₹130 Cr is revenue potential, not FY28 target. Full utilization will take time; we don't assume full capacity in year one.
Industrial segment JV — Aditya Miglani, Burman Capital
AnsweredBroad industrial applications—heavy friction, sealing, lubrication. One customer recently listed on stock exchange. High growth potential in India. We are the best-fit partner for this.
Leadership pipeline — Lakshminarayanan KG, Tunga Investments
Over-AnsweredWe acquire 20–40 management trainees annually from top engineering colleges. Our approach is mentorship-driven, not hire-from-market. We promote within rapidly. We give 20–30% salary jumps and leadership roles to high performers.
Other expenses cost inflation — Nisarg Shah, Pkeday Investments
PartialCOGS control has been excellent (barely 1% rise). New product development and pricing takes real-world costs into account. Power, fuel, logistics have inflated. We will offset with higher growth trajectory and capacity ramps.
Segment wins — Shreyas Gathani, SG Securities
PartialWe don't disclose quarterly wins; we do it half-yearly. Top 10 customers represent bulk of sales. Internationally, we're seeing BMW content uplift. CV faced some headwinds but still posted 40%+ growth.
Non-auto segment definition — Abhishek Jain, KRIIS PMS
DodgedEvery company defines 'auto' differently. Ours is the widest—includes 2/3-wheelers, passenger cars, CVs, farm equipment, LCV, HCV, industrial. Industrial is 48% growth (vs 34% prior promise). Our definition reflects complexity; we're a versatile company.
Mahant Tool Room scale — Shreya Bajaj, Serene Alpha
AnsweredQ2 revenue ₹55 lakh (early stage). Started at ₹2.5 Cr turnover, moving to ₹1 Cr quarterly over 9 months. Growth comes in years 4–5. It's a long-cycle business with certification lead times (18 months minimum for MTR product range).
Aerospace supply shortage — Abhishek Sinha, Bodh Capital
AnsweredWe supply landing gears, doors, spherical bearings to Sukhoi and defense aircraft. Customization is extreme; global competitors sold off aerospace plans due to inability to navigate. NRB thrives in customized aerospace solutions. We have a structural moat here.
Guidance
FY31 ₹2,730 Cr extrapolated from 14.38% CAGR base
MediumFY27 implied baseline ~₹1,500–1,600 Cr; requires sustained mid-teen CAGR. Unitec/MTR ramps support case. No formal FY28/29 milestones given.
Growth trajectory towards 20% (vs prior 15% aspirational)
LowInformal restatement; delivered 18.8% YoY but analysts noted 15% prior guidance. No quantified FY27 full-year target provided.
EBITDA margin 18–20% reaffirmed (annualized)
HighQ2 delivered 18.2%, within range. Management said 'once we reach new growth threshold, sustain and surpass' (implying scalability). Not guaranteeing expansion from 18%, but maintaining range.
₹270 Cr total capex (from prior ₹120 Cr); Unitec JV ₹110 Cr portion
HighUnitec on track April 2027 commissioning. Remaining capex for organic capacity, R&D. Phased across FY27–FY28.
Risks the call surfaced
Margin compression
HighPAT fell 12.5% YoY; NPM compressed from 10.6% to 9.3%. Cost inflation (19% other expense rise) outpacing price realization on new products. JV ramps will absorb capex and R&D, delaying profit inflection.
JV execution risk
MediumUnitec JV (₹110 Cr capex, April 2027 commissioning, ₹130 Cr revenue potential) and Mahant Tool Room (₹55 lakh Q2 revenue, 9-month ramp to ₹1 Cr quarterly) are material to FY28+ growth thesis. Commissioning delays or lower-than-expected ramps would undermine guidance.
Customer concentration
MediumTop 10 customers represent bulk of sales (management stated this explicitly). Loss of single OEM platform (e.g., BMW win delayed, Mahant Tool Room customer defection) could disrupt growth trajectory. No customer >10% of sales mentioned (healthy), but concentration in tier-one OEMs is real.
EV demand execution
MediumEV adjacency (high-frequency drives, commercial EV, e-mobility) is a core 5-year narrative. However, absolute EV revenue today is immaterial; growth dependent on global OEM platform ramps (BMW from Jan 2027, Unitec JV unproven). EV segment growth could stall if OEM cycle delays.
Profit conversion risk
HighCore issue: PAT fell 12.5% YoY despite 18.8% revenue growth. This contradicts management's assertion of 'quality growth' and improved mix. Unless FY28 shows PAT re-acceleration, the long-term ₹2,730 Cr / 18–20% margin thesis will be questioned. Investors may repriced risk of further margin compression.
Management
Score 6/10. Candid on long-term strategy and competitive moat; evasive on near-term metrics. Refused to guide quarterly or semi-annual targets, citing 'conservative' philosophy. Transparent on JV mechanics and customer wins, but vague on cost inflation and margin expansion timeline. Delivered 18.8% revenue YoY (vs 15% prior aspiration, beat), but PAT fell 12.5% (profit execution miss). EBITDA margin 18.2% met range. Track record shows growth top-line, but profit leverage lagging. Capex tracking (Unitec April 2027 on track), but Mahant Tool Room still early-stage (₹55 lakh Q2 revenue).
1 · Apr 2027
Unitec JV commissioning; ramp to ₹130 Cr revenue potential
2 · Jan 2027
BMW platform win; new steering/powertrain bearings in all 2027+ models
3 · H2 FY27
Mahant Tool Room scaling to ₹1 Cr quarterly revenue run-rate (18-month pathway)
The core risk is whether organic profit growth can materialize while funding JVs and product development.
Informational and educational content only. Not investment advice.